How to access Elaprase from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with Hunter syndrome (mucopolysaccharidosis type II, MPS II), an X-linked inherited lysosomal storage disorder, may receive a prescription for Elaprase (idursulfase) from their treating metabolic specialist or paediatric geneticist as enzyme-replacement therapy. Elaprase is FDA-approved in the United States for long-term treatment of Hunter syndrome. In Saudi Arabia, Elaprase may not always be routinely stocked locally, which is why your specialist may be coordinating a named-patient import pathway on your behalf for ongoing weekly infusion supply.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Elaprase is an intravenous enzyme-replacement therapy (recombinant human iduronate-2-sulfatase) administered as a weekly infusion. Eligibility requires biochemical and/or genetic confirmation of Hunter syndrome. The manufacturer is Takeda (via Shire). Dosing is typically 0.5 mg/kg IV once weekly. The product requires refrigerated storage (2-8 degrees C) and reconstitution before infusion. Monitoring includes urinary GAG levels, pulmonary function, cardiac parameters, joint/skeletal status, infusion-reaction surveillance, and antibody response. Your specialist will confirm Hunter syndrome diagnosis and coordinate the infusion plan.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Elaprase legally importable into Saudi Arabia?
Yes, through the Saudi Food and Drug Authority (SFDA) named-patient import framework, administered via the administering hospital's importing pharmacy and the SFDA Pharmacy and Drug Control Department. Saudi Arabia has a mature named-patient mechanism that supports cross-border access to rare-disease enzyme-replacement therapies.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Because Elaprase is cold-chain, chain-of-custody documentation includes continuous temperature logging.
How the pathway works, step by step
- Consultation with your treating specialist. The decision to prescribe Elaprase is clinical, based on Hunter syndrome confirmation and organ-system status. Your specialist documents the rationale.
- Infusion-facility identification. A Saudi tertiary hospital or infusion centre equipped for weekly enzyme-replacement infusions accepts the case.
- SFDA named-patient application. Your physician or the hospital's importing pharmacy files an application with SFDA including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Elaprase travels with validated cold-chain packaging and continuous temperature logging end to end.
- Arrival and infusion. The infusion centre receives the product and administers under your specialist's care. Reserve Meds coordinates the next cycle ahead of depletion, reflecting the weekly cadence.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Hunter syndrome diagnosis and Elaprase as the indicated therapy
- Verification of their Saudi Arabia medical licence (SFDA / QCHP)
- A current prescription naming the product, dose (mg/kg), and weekly infusion schedule
- Patient identifier (anonymised reference preferred)
- The identified infusion facility and its cold-chain handling capability
Reserve Meds provides a physician documentation kit bundling the templates SFDA reviewers expect to see for named-patient import of cold-chain rare-disease enzyme-replacement therapies.
Costs and timing
Elaprase's US cash-pay drug-only reference price is weight-dependent. A typical paediatric annual cost sits in an indicative 2026 drug-only range (delivered quote issued at intake) of roughly USD 400,000-650,000 for ongoing weekly infusions (adult costs scale with weight). Logistics, SFDA documentation handling, cold-chain shipment, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete SFDA application is submitted. Subsequent cycles are scheduled to match the weekly infusion calendar.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Elaprase specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for SFDA review.
- Logistics. Cold-chain shipment and chain-of-custody coordination with temperature logging.
- Concierge case lead. A named point of contact for your family and your physician throughout the weekly-infusion cycle.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating metabolic specialist and the infusion facility.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. The pathway has been used across rare disease for many years. See our trust and compliance page.
Why weekly infusions? Elaprase's pharmacokinetics require weekly dosing to maintain enzyme activity. Your specialist will discuss home-infusion versus hospital-infusion options.
What if the cold chain breaks? Our protocol logs temperature continuously; any excursion is assessed against manufacturer stability data. If the product is compromised, we re-source at our cost per service terms.
Will private insurance or MOH coverage apply? Cash-pay is the default. Some Saudi private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Elaprase coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Elaprase (idursulfase) in Saudi Arabia, 2026
Elaprase (idursulfase) is approved by the US Food and Drug Administration for the labelled indication of enzyme replacement therapy for Hunter syndrome (mucopolysaccharidosis type II, MPS II) (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Elaprase (idursulfase) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Elaprase (idursulfase) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Elaprase (idursulfase) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For recombinant iduronate-2-sulfatase enzyme replacement therapy therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Elaprase (idursulfase) reflects the US wholesale acquisition cost published by the manufacturer (Takeda (formerly Shire)) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Elaprase (idursulfase) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Elaprase (idursulfase) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Elaprase (idursulfase): the labelled indication is enzyme replacement therapy for Hunter syndrome (mucopolysaccharidosis type II, MPS II). The recombinant iduronate-2-sulfatase enzyme replacement therapy mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is MPS II International Consensus Panel and the National MPS Society at mpssociety.org/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Elaprase (idursulfase) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Elaprase (idursulfase); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Elaprase (idursulfase) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Elaprase (idursulfase) remains enzyme replacement therapy for Hunter syndrome (mucopolysaccharidosis type II, MPS II) (see the current FDA approval record at accessdata.fda.gov). Takeda (formerly Shire) continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The MPS II International Consensus Panel and the National MPS Society guidance at mpssociety.org/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.